Core Viewpoint - Jichuan Pharmaceutical (600566) is focusing on the commercialization of a new drug for allergic rhinitis, PG-011 nasal spray, through a partnership with Beijing Puqi Pharmaceutical Technology Co., Ltd. [1][3] Group 1: Commercialization Agreement - Jichuan Pharmaceutical's subsidiary, Jichuan Pharmaceutical Group Co., Ltd., has signed an exclusive commercialization agreement with Puqi Pharmaceutical, granting Jichuan the rights to commercialize PG-011 in China, including mainland, Hong Kong, Macau, and Taiwan [1][3] - The maximum payment for this exclusive commercialization right is capped at 100 million yuan (including tax) [1][3] Group 2: Product Details - PG-011 is a self-developed JAK1/2 inhibitor aimed at treating allergic rhinitis and is expected to be the world's first JAK inhibitor nasal spray [3] - The clinical trial application for PG-011 was approved by the National Medical Products Administration (NMPA) on August 2, 2023, and it is currently in the clinical phase III stage [3] Group 3: Financial Implications for Puqi Pharmaceutical - Puqi Pharmaceutical is currently not profitable, with projected net revenues of 11.22 million yuan and 1.158 million yuan for 2024 and the first three quarters of 2025, respectively, alongside losses of 178 million yuan and 125 million yuan during the same periods [3][4] - The commercialization agreement is expected to provide significant revenue for Puqi Pharmaceutical, which has high R&D expenditures, accounting for 78.2% and 77.7% of total operating expenses in 2024 and the first three quarters of 2025, respectively [4] Group 4: Additional Agreements - Following the agreement with Puqi Pharmaceutical, Jichuan Pharmaceutical also announced a separate exclusive commercialization rights agreement with Jiangsu Jiyuan Pharmaceutical Co., Ltd. and others for the drug Inusimab, with a payment of 80 million yuan (including tax) and potential milestone payments of up to 10 million yuan [4][5] Group 5: Financial Performance of Jichuan Pharmaceutical - Jichuan Pharmaceutical reported a revenue of approximately 3.932 billion yuan for the first three quarters of 2025, a year-on-year decrease of 32.27%, and a net profit of about 1.022 billion yuan, down 46.27% [5] - The company has experienced a decline in both revenue and net profit since 2024, with revenues of approximately 8.017 billion yuan and net profits of about 2.532 billion yuan, reflecting decreases of 16.96% and 10.32%, respectively [5]